News

Carmody Torrance Sandak & Hennessey Welcomes New Leadership

Carmody Torrance Sandak & Hennessey Welcomes New Leadership

Carmody Torrance Sandak & Hennessey Announces New Leadership

Carmody Torrance Sandak & Hennessey LLP is delighted to share the significant news of Fatima Lahnin being appointed as the new Managing Partner as of February 1, 2026. This change marks a new chapter for the firm as Fatima takes on the key role previously held by Rick Street, who led the firm with dedication since 2020.

A Commitment to Growth and Client Service

Fatima's background within the firm is extensive. Having joined Carmody in 2001 and becoming a partner in 2009, she brings vast expertise as an intellectual property trial lawyer. Her experience encompasses substantial involvement in patent infringement cases and other complex intellectual property disputes.

Known for her exceptional capabilities in high-stakes litigation across various federal courts, Fatima has earned respect and recognition in the legal community as a top-tier attorney, noted by prestigious rankings in Benchmark Litigation and Best Lawyers.

Fatima Lahnin's Vision as Managing Partner

Expressing her gratitude upon being appointed, Fatima stated, "I am thankful for Rick Street's leadership and the trust my partners have placed in me. My primary goal moving forward is to continue providing top-quality services to our clients while guiding the firm’s growth in a disciplined manner. The collaborative spirit we share with our clients is vital to our operations, and I aim to prioritize this characteristic as we advance."

Support From Outgoing Leadership

Rick Street, the outgoing Managing Partner, voiced his confidence in Fatima's leadership. He shared, "Carmody rests in excellent hands under Fatima's direction. For 25 years, we have worked together and planned this transition meticulously over the past year. I firmly believe that Fatima is the ideal choice to lead the firm into the future."

Fatima's Educational Background

Fatima earned her Juris Doctor degree from Northeastern University School of Law, solidifying her legal foundation and expertise that she brings to her new role.

About Carmody Torrance Sandak & Hennessey LLP

Carmody Torrance Sandak & Hennessey LLP is noted for its long-standing tradition as a leading full-service law firm in Connecticut, having operated for an impressive 125 years. The firm has grown to include approximately 95 lawyers spread across seven offices statewide. Recent expansions in 2025 and 2023 saw the firm merge with other firms in Connecticut, enhancing its presence and service capacity in regions such as eastern Connecticut.

The firm has a rich history of strategic combinations, notably its merger with Sandak Hennessey & Greco in 2014. This merger fortified its presence in various communities, including Waterbury, New Haven, Southbury, and Litchfield, demonstrating Carmody's commitment to comprehensive service delivery across Connecticut.

Frequently Asked Questions

Who is the new Managing Partner of Carmody Torrance Sandak & Hennessey?

Fatima Lahnin is the newly appointed Managing Partner, starting her role in February 2026.

What is Fatima Lahnin's background?

Fatima has been with the firm since 2001 and has served as a partner since 2009. She specializes in intellectual property law.

What did Rick Street say about Fatima's appointment?

Rick Street expressed confidence in Fatima's leadership, citing their long history of collaboration and his belief that she is the right choice for the firm.

What is the history of Carmody Torrance Sandak & Hennessey LLP?

The firm has been operational for 125 years, with recent expansions enhancing its footprint in Connecticut.

How many lawyers are at Carmody Torrance Sandak & Hennessey LLP?

The firm comprises approximately 95 lawyers across seven offices in the state.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 5

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 9

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 4

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 3

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 6

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 4

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 3

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading

Top 5 Most Recently Viewed Articles

Soleno Therapeutics Celebrates FDA Approval of VYKAT XR for PWS

Updated Category News Views 420

Soleno Therapeutics Announces FDA Approval for VYKAT XR Soleno Therapeutics, Inc. (NASDAQ: SLNO), a notable biopharmaceutical company, has made a significant announcement regarding the U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets. This new treatment targets hyperphagia in individuals aged four and older...

Continue Reading
aTyr Pharma Faces Legal Challenges: Investors Urged to Act

Updated Category News Views 173

aTyr Pharma's Legal Situation and Its Implications Recent developments surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) have caught the attention of investors, particularly as the company faces significant legal challenges. The situation arose from a steep decline in share value triggered by disappointing results from a key clinical trial. This decline, marked by an...

Continue Reading
Primo Brands Boosts Share Repurchase Program by $50 Million

Updated Category News Views 145

Primo Brands Boosts Share Repurchase Program Primo Brands Corporation (NYSE: PRMB) is excited to announce a significant increase in its share repurchase program. This decision, made by the Board of Directors, involves raising the repurchase authorization by $50 million, bringing the total program authorization to an impressive $300 million. This enhancement in the share...

Continue Reading
GOTRAX Partners with RSMG Select to Inspire Youth Movement

Updated Category News Views 83

GOTRAX Teams Up with RSMG Select for Youth Development GOTRAX has embarked on an inspiring journey through its partnership with RSMG Select, aimed at nurturing not just young athletes but the community at large. The collaboration has transformed the experience for youth participating in futsal, allowing for significant growth and empowerment beyond the typical sports...

Continue Reading
Zenas BioPharma Celebrates Major Milestones in Q3 2025

Updated Category News Views 245

Zenas BioPharma Celebrates Major Milestones in Q3 2025 - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end. - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS). - Secured development and commercialization rights for three...

Continue Reading